180 related articles for article (PubMed ID: 38041877)
1. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.
Shen H; Zhu R; Liu Y; Hong Y; Ge J; Xuan J; Niu W; Yu X; Qin JJ; Li Q
Drug Resist Updat; 2024 Jan; 72():101013. PubMed ID: 38041877
[TBL] [Abstract][Full Text] [Related]
2. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
[TBL] [Abstract][Full Text] [Related]
3. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
Satapathy S; Bal C
Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
5. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
Zhao S; Zhao Y; Zhao Y; Wang G
Front Endocrinol (Lausanne); 2023; 14():1320044. PubMed ID: 38313845
[TBL] [Abstract][Full Text] [Related]
6. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
Zhang L; Li Z; Zhang M; Zou H; Bai Y; Liu Y; Lv J; Lv L; Liu P; Deng Z; Liu C
Med Oncol; 2023 Jul; 40(9):258. PubMed ID: 37524925
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
[TBL] [Abstract][Full Text] [Related]
8. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
9. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
10. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.
Li G; Lei J; Song L; Jiang K; Wei T; Li Z; Gong R; Zhu J
Cancer Med; 2018 Nov; 7(11):5448-5456. PubMed ID: 30264548
[TBL] [Abstract][Full Text] [Related]
12. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
Spitzweg C; Bible KC; Hofbauer LC; Morris JC
Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
14. Enhancing Radioiodine Incorporation in
Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
[No Abstract] [Full Text] [Related]
15. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer.
Yu Q; Zhang X; Li L; Zhang C; Huang J; Huang W
Asia Pac J Clin Oncol; 2023 Jun; 19(3):279-289. PubMed ID: 35950297
[TBL] [Abstract][Full Text] [Related]
16. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
de la Fouchardiere C; Alghuzlan A; Bardet S; Borget I; Borson Chazot F; Do Cao C; Godbert Y; Leenhardt L; Zerdoud S; Leboulleux S
Bull Cancer; 2019 Sep; 106(9):812-819. PubMed ID: 31200896
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
18. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
19. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma.
Wang J; Xu Q; Xuan Z; Mao Y; Tang X; Yang K; Song F; Zhu X
Oncologist; 2024 May; ():. PubMed ID: 38760956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
